Why is the ResMed share price climbing today?

ResMed shares are trading ex-dividend.

| More on:
A man holds his hand under his chin as he concentrates on his laptop screen and reads about the ANZ share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • ResMed shares push 1.40% higher to $28.25 
  • The company's shares are trading ex-dividend today 
  • ResMed is set to pay its latest quarterly dividend to eligible shareholders on 16 June 

The ResMed Inc (ASX: RMD) share price is heading north during early Wednesday morning.

At the time of writing, the sleep treatment focused medical device company's shares are up 1.40% to $28.25.

Why are ResMed shares edging higher today? 

Following the company's third quarter results released on 29 April, investors are eyeing ResMed shares as they go ex-dividend today.

While typically a company's shares travel lower on the ex-dividend date, this hasn't been the case this morning. This is because of the heavy losses ResMed has recorded in the past few weeks, hitting an 11-month low of $27.51 yesterday.

It appears that bargain hunters are swooping in to take advantage of the recent share price weakness.

What does this mean for ResMed shareholders?

For those eligible for ResMed's quarterly dividend, shareholders will receive a payment of US 4.2 cents per share on 16 June. The dividend is unfranked, which means investors will unfortunately miss out on the tax credits.

The latest dividend reflects a 7.69% increase when compared to the prior corresponding period (US 3.9 cents per share).

In case you were wondering, the company does not have a dividend reinvestment plan (DRP).

Are ResMed shares a buy now?

Following the company's financial scorecard, a couple of brokers weighed in on the ResMed share price.

The team at Goldman Sachs cut its 12-month price target by 6% to $33.70 for the healthcare company's shares. Its analysts believe that there is still more upside in ResMed shares despite missing its performance targets recently.

Based on the current share price, this implies an upside of about 19% for investors.

Furthermore, Macquarie also slashed its rating on ResMed shares by 2.7% to $36.50 a pop. This also implies an upside of around 29% from where the company trades today.

ResMed share price summary

Over the past 12 months, ResMed shares have gained 14% on the back of positive investor sentiment. On the other hand, the S&P/ASX 200 Index (ASX: XJO) has fallen by 1% over the same timeframe.

ResMed shares reached a 52-week high of $40.49 in August, before backtracking amid inflationary movements and soaring living costs.

Based on today's price, ResMed commands a market capitalisation of roughly $11.41 billion and has a trailing dividend yield of 0.56%.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Man jumps for joy in front of a background of a rising stocks graphic.
Healthcare Shares

Guess which ASX All Ords stock is jumping on big US news

This small cap is catching the eye on Thursday. But why?

Read more »

three excited doctors with hands in the air
Healthcare Shares

Two ASX healthcare shares that could be set to double

This broker has buy recommendations on these two shares. 

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Telix shares jump 7% on big US news

Let's see what is getting investors excited on Wednesday.

Read more »

An older gentleman leans over his partner's shoulder as she looks at a tablet device while seated at a table.
Healthcare Shares

Macquarie tips 28% upside for this ASX healthcare stock

The broker expects big things from this New Zealand retirement village developer and operator.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

$10,000 invested in these ASX healthcare shares 5 years ago is now worth…

These healthcare stocks have brought big returns for investors 

Read more »

A man wearing a white coat and glasses is wide-mouthed in surprise.
Healthcare Shares

Guess which ASX 300 stock is crashing 55% today

What's going on with this stock? Let's see why investors are hitting the sell button.

Read more »

Woman serving customer in pharmacy.
Healthcare Shares

Up 132% in a year, are Sigma Healthcare shares still a good buy post the Chemist Warehouse merger?

After gaining 132% in 12 months, it too late to buy Sigma Healthcare shares today?

Read more »

Three scientists wearing white coats and blue gloves dance together in a lab.
Share Market News

Is it too late to buy Pro Medicus shares?

Pro Medicus shares have risen 550% over 3 years. Have you missed the boat? Three experts weigh in.

Read more »